Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CASH there it is YOUR NEWS
(PR NEWSWIRE) HEE Corporation's Breakthrough Supplement, HPB-84, To Be Manufact
red By The Chemins Company
HEE Corporation's Breakthrough Supplement, HPB-84, To Be Manufactured By The Che
ins Company
HUTCHINSON, Kan., June 29 /PRNewswire/ -- HEE Corporation announced today
that its breakthrough herbal supplement for Pancreatic Health, HPB-84, will be
manufactured by The Chemins Company, Inc. Chemins ( http://www.Chemins.com )
operates under strict good manufacturing practices (GMP's) adhering to
standards certified under A.C.E.R.I.S. accreditation as well as National
Nutritional Foods Association (NNFA)-adopted GMP's (Good Manufacturing
Processes) as directed under the Dietary Supplement Health and Education Act
of 1994 (DSHEA) used by the Food & Drug Administration (FDA). Chemins is
equipped to operate as a self-contained qualitative and quantitative facility
"By manufacturing HEE Corporation's current and future products under the
highest standards of nutritional foods manufacturing, our customers can be
assured of the quality, potency and efficacy of our products," said Radley
Brooks, President of HEE Corporation.
According to the GMP guidelines, the manufacture of HPB-84, and subsequent
products like its HPB-WL2000 weight loss supplement, must meet or exceed high
standards. Every element of the manufacturing process is evaluated, including
personnel, operating procedures, raw material testing, batch production,
quality control, label control, sanitation and analytical laboratory
capabilities. For instance, raw material is pre-tested to verify purity and
potency, and quality records ensure formulations meet label claims. In
addition, an in-house quality control unit has final approval on procedures,
specifications, purity, finished product, product labeling, product
formulations and production records.
"These standards are extremely important to our customers," said Brooks.
"The technical details aren't of interest to most, but our customers
appreciate the fact that HPB-84 is inspected up to 16 different times before
it is shipped to them."
HEE Corp developed the breakthrough nutraceutical, HPB-84, which safely
and effectively promotes stabilized blood glucose levels. For sufferers of
Type II diabetes, HPB-84 addresses three major issues: reducing blood sugar
levels, insulin resistance and promoting insulin production.
About HEE Corporation
Founded in Hutchinson, Kansas in December 2003, HEE Corporation
(OTC: HCCF) is a publicly-traded company committed to improving the quality of
life through the research, development and distribution of products, services
and nutraceuticals that address many of the causes of metabolic syndrome.
Metabolic syndrome is quickly being recognized by the medical community as one
of the most prevalent health conditions in the United States. HPB-84,
manufactured in the United States, is currently sold exclusively through
http://www.hpb84.net . It contains a proprietary blend of the following
ingredients generally recognized by the FDA as safe (GRAS). Complete company
and investor information can be found at the company Web site,
http://www.hee-corp.com .
Forward-Looking and Cautionary Statements
Statements contained in this release may constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements involve a number of risks, uncertainties and other
factors that could cause actual results to differ materially, as discussed in
the company's filings with the Securities and Exchange Commission. HEE
Corporation undertakes neither intention nor obligation to publicly update or
revise any forward-looking statements. HEE Corporation and the HEE Corporation
logo are trademarks or registered trademarks.
Contact: Mark Bouffard
media imPRessions/HEE Corporation
312.222.9590
mbouffard@media-impressions.com
SOURCE HEE Corporation
Contact Information:
Mark Bouffard of media imPRessions for HEE Corporation, +1-312-222-9590, mbouffa
d@media-impressions.com
WebSite:
http://www.Chemins.com
Hee Corp. (OTC: HCCF)
5/2/05 Close .008 Cents
Yes that is correct. This is not a profile, but a stock pick under a penny that had a 52 week high over $1.HCCF just launched a new site http://biz.yahoo.com/prnews/050422/cgf040.html?.v=4 HEE Corporation) has spent the past year testing and developing the promising remedy for Type II diabetes. The introduction of the web site marks the first time HPB-84 has been available for sale to the public.
The HEE Corporation
The HEE Corporation (OTCPK:HCCF) is a publicly traded company that was founded for the purpose of providing a corporate vehicle for marketing a new and extremely promising nutriceutical for Type II Diabetes. This nutriceutical was developed and tested in India . HEE Corp has the world-wide rights (exclusive of India ) and is currently bringing it to the market in the United States and Internationally. Based upon the highly successful results of the product in India , and the testimonials from those who have taken it here in the USA, HEE Corp is very excited about what we can do with the product world-wide.
Type II Diabetes has reached epidemic levels in The United States with 18.2 million confirmed cases and an estimated 5 million (nearly one-third of that total) not yet aware that they have Diabetes! Diabetes is the fifth leading cause of death by disease in the U.S.
Diabetes is now a modern-day epidemic, with some 171,000,000 people around the globe are estimated to have diabetes and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. Type II Diabetes is the cause of many other ailments including heart disease, renal failure, blindness, skin problems and even loss of limbs. While there are treatments available for Diabetes they are often focused on treating the symptoms and not on eradicating the actual disease. Many of the side effects of prescription drugs for diabetes are uncomfortable for the patient and even dangerous.
While this is a relatively new product here in the USA , the promise of this revolutionary product cannot be ignored. While nutriceutical treatments have not received a huge following in the United States they have large followings in the rest of the world. HEE might not change medical history, but our product certainly does have a positive effect on those people who suffer from Type II Diabetes.
Please be aware that this stock trades in 20-30% ranges during the day. We have been adding to our position under .01.The nutriceutical arena will be hot this year.We own a large position bought in the open market and can sell at any time.
This Is a PR that HCCF came out with today. http://biz.yahoo.com/prnews/050503/cgtu041.html?.v=9
Read The last paragraph:
The Board's formation comes at a time when consumer recognition of HEE Corporation and HPB-84 is quickly growing. Over a four-day period last week, (Friday 4-22-05 afternoon through Tuesday 4-26-05), the company's corporate website received 174,000 hits in response to its announcement of HPB-84's availability.
This pick will go to the free list Wed night. We feel this could be our top % gainer of the year.
fair disclosure: We own a position in hccf.030
Hee Corp. (OTC: HCCF)
29-06-2005
Yes that is correct. This is not a profile, but a stock pick under a penny that had a 52 week high over $1.HCCF just launched a new site http://biz.yahoo.com/prnews/050422/cgf040.html?.v=4 HEE Corporation) has spent the past year testing and developing the promising remedy for Type II diabetes. The introduction of the web site marks the first time HPB-84 has been available for sale to the public.
The HEE Corporation
The HEE Corporation (OTCPK:HCCF) is a publicly traded company that was founded for the purpose of providing a corporate vehicle for marketing a new and extremely promising nutriceutical for Type II Diabetes. This nutriceutical was developed and tested in India . HEE Corp has the world-wide rights (exclusive of India ) and is currently bringing it to the market in the United States and Internationally. Based upon the highly successful results of the product in India , and the testimonials from those who have taken it here in the USA, HEE Corp is very excited about what we can do with the product world-wide.
Type II Diabetes has reached epidemic levels in The United States with 18.2 million confirmed cases and an estimated 5 million (nearly one-third of that total) not yet aware that they have Diabetes! Diabetes is the fifth leading cause of death by disease in the U.S.
Diabetes is now a modern-day epidemic, with some 171,000,000 people around the globe are estimated to have diabetes and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. Type II Diabetes is the cause of many other ailments including heart disease, renal failure, blindness, skin problems and even loss of limbs. While there are treatments available for Diabetes they are often focused on treating the symptoms and not on eradicating the actual disease. Many of the side effects of prescription drugs for diabetes are uncomfortable for the patient and even dangerous.
While this is a relatively new product here in the USA , the promise of this revolutionary product cannot be ignored. While nutriceutical treatments have not received a huge following in the United States they have large followings in the rest of the world. HEE might not change medical history, but our product certainly does have a positive effect on those people who suffer from Type II Diabetes.
Please be aware that this stock trades in 20-30% ranges during the day. We have been adding to our position under .01.The nutriceutical arena will be hot this year.We own a large position bought in the open market and can sell at any time.
This Is a PR that HCCF came out with today. http://biz.yahoo.com/prnews/050503/cgtu041.html?.v=9
Read The last paragraph:
The Board's formation comes at a time when consumer recognition of HEE Corporation and HPB-84 is quickly growing. Over a four-day period last week, (Friday 4-22-05 afternoon through Tuesday 4-26-05), the company's corporate website received 174,000 hits in response to its announcement of HPB-84's availability.
This pick will go to the free list Wed night. We feel this could be our top % gainer of the year.
fair disclosure: We own a position in hccf.
BUY BUY BUY BUY BUY
Hee Corp. (OTC: HCCF)
29-06-2005
Yes that is correct. This is not a profile, but a stock pick under a penny that had a 52 week high over $1.HCCF just launched a new site http://biz.yahoo.com/prnews/050422/cgf040.html?.v=4 HEE Corporation) has spent the past year testing and developing the promising remedy for Type II diabetes. The introduction of the web site marks the first time HPB-84 has been available for sale to the public.
The HEE Corporation
The HEE Corporation (OTCPK:HCCF) is a publicly traded company that was founded for the purpose of providing a corporate vehicle for marketing a new and extremely promising nutriceutical for Type II Diabetes. This nutriceutical was developed and tested in India . HEE Corp has the world-wide rights (exclusive of India ) and is currently bringing it to the market in the United States and Internationally. Based upon the highly successful results of the product in India , and the testimonials from those who have taken it here in the USA, HEE Corp is very excited about what we can do with the product world-wide.
Type II Diabetes has reached epidemic levels in The United States with 18.2 million confirmed cases and an estimated 5 million (nearly one-third of that total) not yet aware that they have Diabetes! Diabetes is the fifth leading cause of death by disease in the U.S.
Diabetes is now a modern-day epidemic, with some 171,000,000 people around the globe are estimated to have diabetes and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. Type II Diabetes is the cause of many other ailments including heart disease, renal failure, blindness, skin problems and even loss of limbs. While there are treatments available for Diabetes they are often focused on treating the symptoms and not on eradicating the actual disease. Many of the side effects of prescription drugs for diabetes are uncomfortable for the patient and even dangerous.
While this is a relatively new product here in the USA , the promise of this revolutionary product cannot be ignored. While nutriceutical treatments have not received a huge following in the United States they have large followings in the rest of the world. HEE might not change medical history, but our product certainly does have a positive effect on those people who suffer from Type II Diabetes.
Please be aware that this stock trades in 20-30% ranges during the day. We have been adding to our position under .01.The nutriceutical arena will be hot this year.We own a large position bought in the open market and can sell at any time.
This Is a PR that HCCF came out with today. http://biz.yahoo.com/prnews/050503/cgtu041.html?.v=9
Read The last paragraph:
The Board's formation comes at a time when consumer recognition of HEE Corporation and HPB-84 is quickly growing. Over a four-day period last week, (Friday 4-22-05 afternoon through Tuesday 4-26-05), the company's corporate website received 174,000 hits in response to its announcement of HPB-84's availability.
This pick will go to the free list Wed night. We feel this could be our top % gainer of the year.
fair disclosure: We own a position in hccf.
hccf buy buy
Pilot Study for HPB-84 Shows Positive Results for Diabetes Sufferers
Tuesday June 28, 11:41 am ET
Participants Lowered Glucose Levels, Reduced Dependence on Medication
HUTCHINSON, Kan., June 28 /PRNewswire-FirstCall/ -- Patients participating in a 12-week pilot study for the Type II diabetes supplement HPB-84 successfully reduced blood glucose levels as well as their dependence on oral medication, reported HEE Corporation (OTC: HCCF - News), the manufacturer of HPB-84.
ADVERTISEMENT
The pilot study, which involved 10 test subjects, was conducted to evaluate the efficacy of HPB-84, the breakthrough nutraceutical that safely and effectively addresses the three major issues of Type II diabetes by reducing blood sugar levels and insulin resistance while promoting insulin production. The average participant showed a 26.9 percent decrease in fasting blood glucose levels, and an average of 16 percent decrease in hemoglobin A1C. Prior to the trial, nine of the 10 participants took oral medication and two of the patients were insulin dependent. Four of the nine participants were able to lessen their oral medication, and of the two taking insulin, one reduced the amount taken, while the other was able to completely stop taking insulin.
"We're delighted to see that HPB-84 is having a real, positive impact on the lives of people with Type II diabetes," said Radley Brooks, president of HEE Corp. "Participants and their doctors are encouraged by the results, and people are telling us they feel better than they have in years."
The active ingredients in HPB-84 address the causes of diabetes to improve the quality of life. The ingredients, generally recognized as safe (GRAS) by the FDA, include bitter gourd, naja jihwa, jambul, fenugreek, bengal quince, gurmar and cinnamon. Recent clinical studies show no adverse drug interaction with HPB-84, but it is recommended that customers consult with physicians to determine the proper initial dosage.
Researchers found a number of individual success stories in the trial. One 66-year-old Caucasian male had been a Type II diabetic for thirteen years. At the beginning of the study, he was taking 14 medications and 130-140 units of insulin per day. By the end of the study, he was taking only six medications, no longer required insulin injections, and his fasting blood glucose level fell from a range of 124-155 to 99-134. A second participant reduced his average fasting blood glucose level to 110 from 270, lost 18 pounds, and is now taking half the dosage of his prescription medications.
Most Type II diabetes patients will start seeing positive results from taking HPB-84 within a short period of time, sometimes within a week, but results vary depending on the severity of symptoms, prescription medication and weight. As part of a comprehensive diabetes management program, HEE Corp recommends that diabetes patients talk with their physician, diabetic clinician and nutrition professional to closely monitor their weight, diet and glucose levels while taking HPB-84. HPB-84 is sold exclusively through the Web site http://www.hpb84.net .
About HEE
Founded in Hutchinson, Kansas in December 2003, HEE Corporation (OTC: HCCF - News) is a publicly-traded company committed to improving the quality of life through the research, development and distribution of products, services and nutraceuticals that address many of the causes of metabolic syndrome. Metabolic syndrome is quickly being recognized by the medical community as one of the most prevalent health conditions in the United States. HPB-84, manufactured in the United States, is currently sold exclusively through http://www.hpb84.net . It contains a proprietary blend of the following ingredients generally recognized by the FDA as safe (GRAS). Complete company and investor information can be found at the company Web site, http://www.hee-corp.com .
Forward-Looking and Cautionary Statements
Statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the company's filings with the Securities and Exchange Commission. HEE Corporation undertakes neither intention nor obligation to publicly update or revise any forward-looking statements. HEE Corporation and the HEE Corporation logo are trademarks or registered trademarks.
Contact: Mark Bouffard
media imPRessions/HEE Corporation
312.222.9590
mbouffard@media-impressions.com
BUY BUY 15 julie 0.04
Pilot Study for HPB-84 Shows Positive Results for Diabetes Sufferers
Tuesday June 28, 11:41 am ET
Participants Lowered Glucose Levels, Reduced Dependence on Medication
HUTCHINSON, Kan., June 28 /PRNewswire-FirstCall/ -- Patients participating in a 12-week pilot study for the Type II diabetes supplement HPB-84 successfully reduced blood glucose levels as well as their dependence on oral medication, reported HEE Corporation (OTC: HCCF - News), the manufacturer of HPB-84.
ADVERTISEMENT
The pilot study, which involved 10 test subjects, was conducted to evaluate the efficacy of HPB-84, the breakthrough nutraceutical that safely and effectively addresses the three major issues of Type II diabetes by reducing blood sugar levels and insulin resistance while promoting insulin production. The average participant showed a 26.9 percent decrease in fasting blood glucose levels, and an average of 16 percent decrease in hemoglobin A1C. Prior to the trial, nine of the 10 participants took oral medication and two of the patients were insulin dependent. Four of the nine participants were able to lessen their oral medication, and of the two taking insulin, one reduced the amount taken, while the other was able to completely stop taking insulin.
"We're delighted to see that HPB-84 is having a real, positive impact on the lives of people with Type II diabetes," said Radley Brooks, president of HEE Corp. "Participants and their doctors are encouraged by the results, and people are telling us they feel better than they have in years."
The active ingredients in HPB-84 address the causes of diabetes to improve the quality of life. The ingredients, generally recognized as safe (GRAS) by the FDA, include bitter gourd, naja jihwa, jambul, fenugreek, bengal quince, gurmar and cinnamon. Recent clinical studies show no adverse drug interaction with HPB-84, but it is recommended that customers consult with physicians to determine the proper initial dosage.
Researchers found a number of individual success stories in the trial. One 66-year-old Caucasian male had been a Type II diabetic for thirteen years. At the beginning of the study, he was taking 14 medications and 130-140 units of insulin per day. By the end of the study, he was taking only six medications, no longer required insulin injections, and his fasting blood glucose level fell from a range of 124-155 to 99-134. A second participant reduced his average fasting blood glucose level to 110 from 270, lost 18 pounds, and is now taking half the dosage of his prescription medications.
Most Type II diabetes patients will start seeing positive results from taking HPB-84 within a short period of time, sometimes within a week, but results vary depending on the severity of symptoms, prescription medication and weight. As part of a comprehensive diabetes management program, HEE Corp recommends that diabetes patients talk with their physician, diabetic clinician and nutrition professional to closely monitor their weight, diet and glucose levels while taking HPB-84. HPB-84 is sold exclusively through the Web site http://www.hpb84.net .
About HEE
Founded in Hutchinson, Kansas in December 2003, HEE Corporation (OTC: HCCF - News) is a publicly-traded company committed to improving the quality of life through the research, development and distribution of products, services and nutraceuticals that address many of the causes of metabolic syndrome. Metabolic syndrome is quickly being recognized by the medical community as one of the most prevalent health conditions in the United States. HPB-84, manufactured in the United States, is currently sold exclusively through http://www.hpb84.net . It contains a proprietary blend of the following ingredients generally recognized by the FDA as safe (GRAS). Complete company and investor information can be found at the company Web site, http://www.hee-corp.com .
Forward-Looking and Cautionary Statements
Statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the company's filings with the Securities and Exchange Commission. HEE Corporation undertakes neither intention nor obligation to publicly update or revise any forward-looking statements. HEE Corporation and the HEE Corporation logo are trademarks or registered trademarks.
Contact: Mark Bouffard
media imPRessions/HEE Corporation
312.222.9590
mbouffard@media-impressions.com
BUY BUY 15 julie 0.04
Pilot Study for HPB-84 Shows Positive Results for Diabetes Sufferers
Tuesday June 28, 11:41 am ET
Participants Lowered Glucose Levels, Reduced Dependence on Medication
HUTCHINSON, Kan., June 28 /PRNewswire-FirstCall/ -- Patients participating in a 12-week pilot study for the Type II diabetes supplement HPB-84 successfully reduced blood glucose levels as well as their dependence on oral medication, reported HEE Corporation (OTC: HCCF - News), the manufacturer of HPB-84.
ADVERTISEMENT
The pilot study, which involved 10 test subjects, was conducted to evaluate the efficacy of HPB-84, the breakthrough nutraceutical that safely and effectively addresses the three major issues of Type II diabetes by reducing blood sugar levels and insulin resistance while promoting insulin production. The average participant showed a 26.9 percent decrease in fasting blood glucose levels, and an average of 16 percent decrease in hemoglobin A1C. Prior to the trial, nine of the 10 participants took oral medication and two of the patients were insulin dependent. Four of the nine participants were able to lessen their oral medication, and of the two taking insulin, one reduced the amount taken, while the other was able to completely stop taking insulin.
"We're delighted to see that HPB-84 is having a real, positive impact on the lives of people with Type II diabetes," said Radley Brooks, president of HEE Corp. "Participants and their doctors are encouraged by the results, and people are telling us they feel better than they have in years."
The active ingredients in HPB-84 address the causes of diabetes to improve the quality of life. The ingredients, generally recognized as safe (GRAS) by the FDA, include bitter gourd, naja jihwa, jambul, fenugreek, bengal quince, gurmar and cinnamon. Recent clinical studies show no adverse drug interaction with HPB-84, but it is recommended that customers consult with physicians to determine the proper initial dosage.
Researchers found a number of individual success stories in the trial. One 66-year-old Caucasian male had been a Type II diabetic for thirteen years. At the beginning of the study, he was taking 14 medications and 130-140 units of insulin per day. By the end of the study, he was taking only six medications, no longer required insulin injections, and his fasting blood glucose level fell from a range of 124-155 to 99-134. A second participant reduced his average fasting blood glucose level to 110 from 270, lost 18 pounds, and is now taking half the dosage of his prescription medications.
Most Type II diabetes patients will start seeing positive results from taking HPB-84 within a short period of time, sometimes within a week, but results vary depending on the severity of symptoms, prescription medication and weight. As part of a comprehensive diabetes management program, HEE Corp recommends that diabetes patients talk with their physician, diabetic clinician and nutrition professional to closely monitor their weight, diet and glucose levels while taking HPB-84. HPB-84 is sold exclusively through the Web site http://www.hpb84.net .
About HEE
Founded in Hutchinson, Kansas in December 2003, HEE Corporation (OTC: HCCF - News) is a publicly-traded company committed to improving the quality of life through the research, development and distribution of products, services and nutraceuticals that address many of the causes of metabolic syndrome. Metabolic syndrome is quickly being recognized by the medical community as one of the most prevalent health conditions in the United States. HPB-84, manufactured in the United States, is currently sold exclusively through http://www.hpb84.net . It contains a proprietary blend of the following ingredients generally recognized by the FDA as safe (GRAS). Complete company and investor information can be found at the company Web site, http://www.hee-corp.com .
Forward-Looking and Cautionary Statements
Statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the company's filings with the Securities and Exchange Commission. HEE Corporation undertakes neither intention nor obligation to publicly update or revise any forward-looking statements. HEE Corporation and the HEE Corporation logo are trademarks or registered trademarks.
Contact: Mark Bouffard
media imPRessions/HEE Corporation
312.222.9590
mbouffard@media-impressions.com
NEWS
HEE Corporation Announces Enthusiastic Response to the Online Ordering of HPB84
PR Newswire - June 27, 2005 11:56
HUTCHINSON, Kan., June 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- HEE Corporation (OTC: HCCF), would like to announce they are receiving a very positive response to the online availability of their proprietary product for Type II diabetes, HPB84. The e-commerce website http://www.hpb84.net which went live in April 2005, has consistently been receiving over 110,000 hits per month.
These inquiries have resulted in favorable orders for the product which is now manufactured, according to the highest quality standards, in Colorado. Along with the positive response to our website, strong interest has been shown by the medical community ranging from Nutritionists to Medical Doctors. Additionally, HEE Corporation is using the opportunity to finalize some potentially lucrative marketing agreements.
A company spokesperson commented, "HEE Corporation eagerly awaits the positive response our product, HPB84, will generate once it is distributed to our many customers. For us, there is no better way to market the product than by word of mouth and the positive testimonies of our customers. The more product we have out there, the more positive responses our shareholders will hear. It is my personal belief that this nutraceutical is going to revolutionize how people look at managing Type 2 Diabetes." The representative went on to say, "I know there are many skeptics out there who have doubts about our product, but once they give it a trial I feel confident that HPB84 will greatly improve their quality of life."
Mr. J. Young of Kansas who has had the opportunity to use this product had the following to say about HPB84.
Before I began using HPB-84, I had mostly resigned myself to living with blood glucose levels from the high 100's to the mid to high 200's, along with an Hga1c running in the low 7s. It was not a healthy situation, but I seemed to not be able to lower it with diet and exercise alone. I was initially skeptical of some of the claims made; plus, there were no real clinical studies to refer to. As time went on, I continued to hear of and see for myself results from individuals taking HPB-84. I finally began my use with the attitude of, "What do I have to lose?" The first 5 to 6 weeks, there was no discernible change in my levels, other than that they became somewhat more stable. I returned to the product website and discovered my dosage was incorrect. I adjusted my dosage accordingly and things began to happen. Weeks 7 and 8 my average blood glucose reading decreased to the low 120s. Week 9, I averaged in the low 110s. In weeks 10 and 11, I hit the low 100s. Weeks 12 and 13 saw me again in the mid 110s. At this time I went for another Hga1c test. The results were a pleasant surprise: I had dropped .7 points, to 6.4. This improvement came at the end of 7 weeks of correct dosage levels. In 90 days, at my next Hga1c, I can only guess and hope at what further improvement I'll see. A modest weight loss has accompanied these changes; my appetite has definitely decreased. With the weight loss (14 lbs. dating from week one) has come more energy and a seemingly higher level of wellness and alertness. A recent lipid profile and liver study have indicated no adverse changes in liver or kidney function. Also, the loss of feeling in my lower extremities due to diabetes induced peripheral neuropathy, has begun to recede. I have regained sensation in my feet during the last three months. I feel this is in direct relation to the lowering of my blood glucose levels and Hga1c numbers from HPB-84.
Thank you for a product that is giving me the chance to acquire and maintain better health.
Sincerely,
J. Young
Kansas
O.K. I'm back its 1660 "road miles" portal to portal. Not to be confused with "cyber miles". I am not sorry to report that all the negative and bashing posters are just putting out a lot of junk. I will be the first to admit that I went there with a postive bias and left with an even greater one.I did not find any surprises in that I saw exactly what I expected. I was very much impressed with both Darci and Radleys ability to sucessfully manage HEE. It appeared to me that Darci holds down the fort while Radley does the bear hunting, altho both are equally capable of performing the others job. They are both very excited about the future of this little company. Other than family, I would say that this company represents one of the most important elements in both their lives. They are aggressively searching for more ways and means to improve and grow this into a much larger operation. This is illustrated by the fact that they are already "bumper to bumper" coming out with two other products, and they haven't stopped searching yet. I did not see one indicator pointing to a possible problem area beyond their capability. I left with the intent of creating a program to acquire HCCF on a regular and long term basis. I fully intend to be a part of HEE for several years. It's amazing to realize what they have been able to accomplish in such a very short time. I have visited many companies large , medium and small and I sincerely believe they have the ability to grow this project into a major corporation.
O.K. I'm back its 1660 "road miles" portal to portal. Not to be confused with "cyber miles". I am not sorry to report that all the negative and bashing posters are just putting out a lot of junk. I will be the first to admit that I went there with a postive bias and left with an even greater one.I did not find any surprises in that I saw exactly what I expected. I was very much impressed with both Darci and Radleys ability to sucessfully manage HEE. It appeared to me that Darci holds down the fort while Radley does the bear hunting, altho both are equally capable of performing the others job. They are both very excited about the future of this little company. Other than family, I would say that this company represents one of the most important elements in both their lives. They are aggressively searching for more ways and means to improve and grow this into a much larger operation. This is illustrated by the fact that they are already "bumper to bumper" coming out with two other products, and they haven't stopped searching yet. I did not see one indicator pointing to a possible problem area beyond their capability. I left with the intent of creating a program to acquire HCCF on a regular and long term basis. I fully intend to be a part of HEE for several years. It's amazing to realize what they have been able to accomplish in such a very short time. I have visited many companies large , medium and small and I sincerely believe they have the ability to grow this project into a major corporation.
Eye wittness report.
--------------------------------------------------------------------------------
From RB
O.K. I'm back its 1660 "road miles" portal to portal. Not to be confused with "cyber miles". I am not sorry to report that all the negative and bashing posters are just putting out a lot of junk. I will be the first to admit that I went there with a postive bias and left with an even greater one.I did not find any surprises in that I saw exactly what I expected. I was very much impressed with both Darci and Radleys ability to sucessfully manage HEE. It appeared to me that Darci holds down the fort while Radley does the bear hunting, altho both are equally capable of performing the others job. They are both very excited about the future of this little company. Other than family, I would say that this company represents one of the most important elements in both their lives. They are aggressively searching for more ways and means to improve and grow this into a much larger operation. This is illustrated by the fact that they are already "bumper to bumper" coming out with two other products, and they haven't stopped searching yet. I did not see one indicator pointing to a possible problem area beyond their capability. I left with the intent of creating a program to acquire HCCF on a regular and long term basis. I fully intend to be a part of HEE for several years. It's amazing to realize what they have been able to accomplish in such a very short time. I have visited many companies large , medium and small and I sincerely believe they have the ability to grow this project into a major corporation.
Sussex Avenue Partners has a feature profile of ASNI on their website. They sent an e-mail yesterday to their subscriber list which I am told numbers in the "tens of thousands". Here's the text of the e-mail.
Atlantic Syndication Network, Inc. (“ASNI” or the “Company”) provides creative, design, and development services for television shows, commercials, and infomercials. The Company’s strengths include research and development of cutting-edge programming for online webcasting of streaming video.
http://www.sussexavenueprofiles.com
Hee Corp. (OTC: HCCF)
22-06-2005/Close .004
Yes that is correct. This is not a profile, but a stock pick under a penny that had a 52 week high over $1.HCCF just launched a new site http://biz.yahoo.com/prnews/050422/cgf040.html?.v=4 HEE Corporation) has spent the past year testing and developing the promising remedy for Type II diabetes. The introduction of the web site marks the first time HPB-84 has been available for sale to the public.
The HEE Corporation
The HEE Corporation (OTCPK:HCCF) is a publicly traded company that was founded for the purpose of providing a corporate vehicle for marketing a new and extremely promising nutriceutical for Type II Diabetes. This nutriceutical was developed and tested in India . HEE Corp has the world-wide rights (exclusive of India ) and is currently bringing it to the market in the United States and Internationally. Based upon the highly successful results of the product in India , and the testimonials from those who have taken it here in the USA, HEE Corp is very excited about what we can do with the product world-wide.
Type II Diabetes has reached epidemic levels in The United States with 18.2 million confirmed cases and an estimated 5 million (nearly one-third of that total) not yet aware that they have Diabetes! Diabetes is the fifth leading cause of death by disease in the U.S.
Diabetes is now a modern-day epidemic, with some 171,000,000 people around the globe are estimated to have diabetes and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. Type II Diabetes is the cause of many other ailments including heart disease, renal failure, blindness, skin problems and even loss of limbs. While there are treatments available for Diabetes they are often focused on treating the symptoms and not on eradicating the actual disease. Many of the side effects of prescription drugs for diabetes are uncomfortable for the patient and even dangerous.
While this is a relatively new product here in the USA , the promise of this revolutionary product cannot be ignored. While nutriceutical treatments have not received a huge following in the United States they have large followings in the rest of the world. HEE might not change medical history, but our product certainly does have a positive effect on those people who suffer from Type II Diabetes.
Please be aware that this stock trades in 20-30% ranges during the day. We have been adding to our position under .01.The nutriceutical arena will be hot this year.We own a large position bought in the open market and can sell at any time.
1 Year price target : .30 Cents
This Is a PR that HCCF came out with today. http://biz.yahoo.com/prnews/050503/cgtu041.html?.v=9
Read The last paragraph:
The Board's formation comes at a time when consumer recognition of HEE Corporation and HPB-84 is quickly growing. Over a four-day period last week, (Friday 4-22-05 afternoon through Tuesday 4-26-05), the company's corporate website received 174,000 hits in response to its announcement of HPB-84's availability.
This pick will go to the free list Wed night. We feel this could be our top % gainer of the year.
fair disclosure: We own a position in hccf.
BUY BUY
Mr.Oops was There!!!I love the guy!!!HCCF HCCF
Darci wrote:
Dear Dr. Haith,
Thank you for your e-mail. To answer your question as to whether we are going to TALK to the investors about your main concern, the answer is YES. We will be filing an updated 15c2-11 on or around July 15, 2005. At that time, all questions will be answered and there will also be a press release out on the subject of the stock by that time as well. I have also been told that it will be addressed through the chairman's newsletter on our hee-corp website.
Also, if you care to let everyone know, "Mr. Oops" visited our office this morning! The trip that he had planned got cancelled, but since he had given his word to everybody on the board that he would visit, he drove all the way from Kentucky, stayed for a little while this morning, and then got back in his vehicle and drove back towards Kentucky. What a guy!!! He said that he should be home tomorrow evening and I'm sure he will be putting out his full report on his findings shortly after that.
I hope that this answers your questions. Have a great weekend.
Darci
Darci Brooks
Director of Investor Relations
HEE Corporation (HCCF.PK)
darci@hee-corp.com
(620)663-3333
Mr.Oops was There!!!I love the guy!!!
Darci wrote:
Dear Dr. Haith,
Thank you for your e-mail. To answer your question as to whether we are going to TALK to the investors about your main concern, the answer is YES. We will be filing an updated 15c2-11 on or around July 15, 2005. At that time, all questions will be answered and there will also be a press release out on the subject of the stock by that time as well. I have also been told that it will be addressed through the chairman's newsletter on our hee-corp website.
Also, if you care to let everyone know, "Mr. Oops" visited our office this morning! The trip that he had planned got cancelled, but since he had given his word to everybody on the board that he would visit, he drove all the way from Kentucky, stayed for a little while this morning, and then got back in his vehicle and drove back towards Kentucky. What a guy!!! He said that he should be home tomorrow evening and I'm sure he will be putting out his full report on his findings shortly after that.
I hope that this answers your questions. Have a great weekend.
Darci
Darci Brooks
Director of Investor Relations
HEE Corporation (HCCF.PK)
darci@hee-corp.com
(620)663-3333
News coming? HCCF HCCF.010
HCCFDrug helps some diabetics make insulin
Treatment lessens need for shots; side effect could raise blood risks
The Associated Press
Updated: 5:11 p.m. ET June 22, 2005
A novel experimental treatment showed promise in a small study for helping certain diabetics retain some ability to make insulin, potentially lessening their need for shots of the hormone to regulate blood sugar levels.
But the experiment raised safety concerns: Most who got the treatment had side effects that researchers said were temporary, but that theoretically might increase their risk of a blood disorder later on.
Nevertheless, the Juvenile Diabetes Research Foundation, which funded the work, considered the results encouraging enough to plan future large-scale studies, which would be needed before the experimental drug might be available.
“The results are very promising. There are not many instances where you can stop an autoimmune disease in its tracks,” said Dr. Richard Insel, the foundation’s executive vice president for research.
Results were published in Thursday’s New England Journal of Medicine.
More than 18 million people in the United State have diabetes. The vast majority have Type 2, which is linked to obesity and occurs when the body can’t effectively use the insulin it makes.
Flulike side effects
The new study involved the other 5 percent to 10 percent of diabetics who have Type 1, which occurs when the body’s immune system attacks and destroys insulin-producing cells in the pancreas. They must get insulin through shots or a pump.
Researchers led by Dr. Lucienne Chatenoud of Necker Hospital in Paris tested the novel approach on 80 newly diagnosed diabetics who still had some insulin function left. The patients were given an experimental drug called anti-CD3 antibody to prevent the immune system attack.
Half of the patients received it and the other half got a dummy drug for a week after they were diagnosed as diabetics. Both groups also got at least three insulin shots a day to control blood sugar.
After 1½ years, the placebo group lost an average one-third of its insulin production ability and needed 50 percent more insulin in shots to regulate blood sugar. The group that got the drug, on the other hand, lowered insulin dependence by 12 percent and increased insulin-making capability. The drug worked best in patients who still had about half of their insulin function remaining.
However, nearly all the people who took the drug had symptoms of mononucleosis, a white-blood-cell disorder caused by a virus, and flulike symptoms including fever and headache.
Researchers said the side effects were minor and short-lived. But Dr. Ake Lernmark, a professor of medicine at the University of Washington, Seattle, wrote in an accompanying editorial that more research is needed to address the drug’s safety.
Lernmark, who had no role in the study, also noted that the drug’s benefits might be limited in patients who already have greater insulin function than typical Type 1 patients. Most Type 1 diabetics are diagnosed when they have already lost 90 percent of their insulin-making ability.
The federal government is currently supporting two studies of the drug in Type 1 patients, said Dr. Judith Fradkin of the National Institute of Diabetes and Digestive and Kidney Diseases.
Several of the researchers in the study reported getting consulting fees and holding stocks options from TolerRx, Inc., a Cambridge, Mass., firm that developed the drug.
© 2005 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
© 2005 MSNBC.com
URL: http://www.msnbc.msn.com/id/8319878/
Wil graag informatie over HTB84 pil tegen diabete
HCCF BUY 37%
Hee Corp. (OTC: HCCF)
5/2/05 Close .008 Cents
Yes that is correct. This is not a profile, but a stock pick under a penny that had a 52 week high over $1.HCCF just launched a new site http://biz.yahoo.com/prnews/050422/cgf040.html?.v=4 HEE Corporation) has spent the past year testing and developing the promising remedy for Type II diabetes. The introduction of the web site marks the first time HPB-84 has been available for sale to the public.
The HEE Corporation
The HEE Corporation (OTCPK:HCCF) is a publicly traded company that was founded for the purpose of providing a corporate vehicle for marketing a new and extremely promising nutriceutical for Type II Diabetes. This nutriceutical was developed and tested in India . HEE Corp has the world-wide rights (exclusive of India ) and is currently bringing it to the market in the United States and Internationally. Based upon the highly successful results of the product in India , and the testimonials from those who have taken it here in the USA, HEE Corp is very excited about what we can do with the product world-wide.
Type II Diabetes has reached epidemic levels in The United States with 18.2 million confirmed cases and an estimated 5 million (nearly one-third of that total) not yet aware that they have Diabetes! Diabetes is the fifth leading cause of death by disease in the U.S.
Diabetes is now a modern-day epidemic, with some 171,000,000 people around the globe are estimated to have diabetes and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. Type II Diabetes is the cause of many other ailments including heart disease, renal failure, blindness, skin problems and even loss of limbs. While there are treatments available for Diabetes they are often focused on treating the symptoms and not on eradicating the actual disease. Many of the side effects of prescription drugs for diabetes are uncomfortable for the patient and even dangerous.
While this is a relatively new product here in the USA , the promise of this revolutionary product cannot be ignored. While nutriceutical treatments have not received a huge following in the United States they have large followings in the rest of the world. HEE might not change medical history, but our product certainly does have a positive effect on those people who suffer from Type II Diabetes.
Please be aware that this stock trades in 20-30% ranges during the day. We have been adding to our position under .01.The nutriceutical arena will be hot this year.We own a large position bought in the open market and can sell at any time.
1 Year price target : .30 Cents
This Is a PR that HCCF came out with today. http://biz.yahoo.com/prnews/050503/cgtu041.html?.v=9
Read The last paragraph:
The Board's formation comes at a time when consumer recognition of HEE Corporation and HPB-84 is quickly growing. Over a four-day period last week, (Friday 4-22-05 afternoon through Tuesday 4-26-05), the company's corporate website received 174,000 hits in response to its announcement of HPB-84's availability.
This pick will go to the free list Wed night. We feel this could be our top % gainer of the year.
fair disclosure: We own a position in hccf.
BUY BUY
Hee Corp. (OTC: HCCF)
5/2/05 Close .008 Cents
Yes that is correct. This is not a profile, but a stock pick under a penny that had a 52 week high over $1.HCCF just launched a new site http://biz.yahoo.com/prnews/050422/cgf040.html?.v=4 HEE Corporation) has spent the past year testing and developing the promising remedy for Type II diabetes. The introduction of the web site marks the first time HPB-84 has been available for sale to the public.
The HEE Corporation
The HEE Corporation (OTCPK:HCCF) is a publicly traded company that was founded for the purpose of providing a corporate vehicle for marketing a new and extremely promising nutriceutical for Type II Diabetes. This nutriceutical was developed and tested in India . HEE Corp has the world-wide rights (exclusive of India ) and is currently bringing it to the market in the United States and Internationally. Based upon the highly successful results of the product in India , and the testimonials from those who have taken it here in the USA, HEE Corp is very excited about what we can do with the product world-wide.
Type II Diabetes has reached epidemic levels in The United States with 18.2 million confirmed cases and an estimated 5 million (nearly one-third of that total) not yet aware that they have Diabetes! Diabetes is the fifth leading cause of death by disease in the U.S.
Diabetes is now a modern-day epidemic, with some 171,000,000 people around the globe are estimated to have diabetes and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. Type II Diabetes is the cause of many other ailments including heart disease, renal failure, blindness, skin problems and even loss of limbs. While there are treatments available for Diabetes they are often focused on treating the symptoms and not on eradicating the actual disease. Many of the side effects of prescription drugs for diabetes are uncomfortable for the patient and even dangerous.
While this is a relatively new product here in the USA , the promise of this revolutionary product cannot be ignored. While nutriceutical treatments have not received a huge following in the United States they have large followings in the rest of the world. HEE might not change medical history, but our product certainly does have a positive effect on those people who suffer from Type II Diabetes.
Please be aware that this stock trades in 20-30% ranges during the day. We have been adding to our position under .01.The nutriceutical arena will be hot this year.We own a large position bought in the open market and can sell at any time.
1 Year price target : .30 Cents
This Is a PR that HCCF came out with today. http://biz.yahoo.com/prnews/050503/cgtu041.html?.v=9
Read The last paragraph:
The Board's formation comes at a time when consumer recognition of HEE Corporation and HPB-84 is quickly growing. Over a four-day period last week, (Friday 4-22-05 afternoon through Tuesday 4-26-05), the company's corporate website received 174,000 hits in response to its announcement of HPB-84's availability.
This pick will go to the free list Wed night. We feel this could be our top % gainer of the year.
fair disclosure: We own a position in hccf.
BUY BUY
Allegros-Flight Your wax himself always very resolved on this share, how reorganisation now that, however, gladly dedicates all of a sudden to the company still just as time to put I myself everything on rijdje wants laws for which this way many shars have been sold or the company himself shars on the free trade verkocht.ik will hear of your.
By: kerry67801
23 Jun 2005, 12:56 PM EDT
Msg. 12864 of 12869
Jump to msg. #
Reply today from Darci,
Dear Kerry,
We would love to have you visit HEE Corp. Just let me know when it is convenient for you. We are here Monday through Friday, usually from 8:30am until 4:30pm or after. You're welcome to come anytime, but if you let me know when it is convenient for you I will make sure that we clear the schedule for that time.
Thanks for getting in contact with us. We will all be happy to meet you.
Kind regards,
Darci Brooks
Director of Investor Relations
HEE Corporation (HCCF.PK)
www.hee-corp.com
darci@hee-corp.com
(620)663-3333
Up 73% on 273,500 volume!!! Looks like a good combination between ASNI and Sussex Ave Partners.
Check out the latest update on the website. They added some very nice touches in the past couple of days.
ASNI BUY 010
Drug helps some diabetics make insulin
Treatment lessens need for shots; side effect could raise blood risks
The Associated Press
Updated: 5:11 p.m. ET June 22, 2005
A novel experimental treatment showed promise in a small study for helping certain diabetics retain some ability to make insulin, potentially lessening their need for shots of the hormone to regulate blood sugar levels.
But the experiment raised safety concerns: Most who got the treatment had side effects that researchers said were temporary, but that theoretically might increase their risk of a blood disorder later on.
Nevertheless, the Juvenile Diabetes Research Foundation, which funded the work, considered the results encouraging enough to plan future large-scale studies, which would be needed before the experimental drug might be available.
“The results are very promising. There are not many instances where you can stop an autoimmune disease in its tracks,” said Dr. Richard Insel, the foundation’s executive vice president for research.
Results were published in Thursday’s New England Journal of Medicine.
More than 18 million people in the United State have diabetes. The vast majority have Type 2, which is linked to obesity and occurs when the body can’t effectively use the insulin it makes.
Flulike side effects
The new study involved the other 5 percent to 10 percent of diabetics who have Type 1, which occurs when the body’s immune system attacks and destroys insulin-producing cells in the pancreas. They must get insulin through shots or a pump.
Researchers led by Dr. Lucienne Chatenoud of Necker Hospital in Paris tested the novel approach on 80 newly diagnosed diabetics who still had some insulin function left. The patients were given an experimental drug called anti-CD3 antibody to prevent the immune system attack.
Half of the patients received it and the other half got a dummy drug for a week after they were diagnosed as diabetics. Both groups also got at least three insulin shots a day to control blood sugar.
After 1½ years, the placebo group lost an average one-third of its insulin production ability and needed 50 percent more insulin in shots to regulate blood sugar. The group that got the drug, on the other hand, lowered insulin dependence by 12 percent and increased insulin-making capability. The drug worked best in patients who still had about half of their insulin function remaining.
However, nearly all the people who took the drug had symptoms of mononucleosis, a white-blood-cell disorder caused by a virus, and flulike symptoms including fever and headache.
Researchers said the side effects were minor and short-lived. But Dr. Ake Lernmark, a professor of medicine at the University of Washington, Seattle, wrote in an accompanying editorial that more research is needed to address the drug’s safety.
Lernmark, who had no role in the study, also noted that the drug’s benefits might be limited in patients who already have greater insulin function than typical Type 1 patients. Most Type 1 diabetics are diagnosed when they have already lost 90 percent of their insulin-making ability.
The federal government is currently supporting two studies of the drug in Type 1 patients, said Dr. Judith Fradkin of the National Institute of Diabetes and Digestive and Kidney Diseases.
Several of the researchers in the study reported getting consulting fees and holding stocks options from TolerRx, Inc., a Cambridge, Mass., firm that developed the drug.
© 2005 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
© 2005 MSNBC.com
URL: http://www.msnbc.msn.com/id/8319878/
To be Fair with all:
Email from Darci!!
Darci wrote:
Date: Wed, 22 Jun 2005 12:23:18 -0600
Dear Dr. Haith,
I am not a director of the company, therefore the updates that I receive on shares are the ones that we make public. Also, I can not give out information to one investor that the company can not give out to all investors at the same time. The one piece of information that I can give you that may be helpful is that the number of shares that are authorized has not been increased. I hope this is helpful to you.
I appreciate that you are a believer and a large shareholder in this company. This company is near and dear to my heart and I look forward to seeing it be successful. Our investors are very important and we do not want anybody to loose money from investing in HEE. This company and product has so much potential! We are working hard to improve it and grow it everyday.
Please stay in touch, and again, thank you for your continued support.
Darci Brooks
Director of Investor Relations
HEE Corporation (HCCF.PK)
www.hee-corp.com
darci@hee-corp.com
(620)663-3333
The new ASNi.TV website is up and running... 10k filed today.
just go to http://www.asni.tv
This should give everyone a good idea of what is happening over at ASNI...
ASNI 73% BUY BUY
ASNI 53%
asni Sussex Avenue Partners has a feature profile of ASNI on their website. They sent an e-mail yesterday to their subscriber list which I am told numbers in the "tens of thousands". Here's the text of the e-mail.
Atlantic Syndication Network, Inc. (“ASNI” or the “Company”) provides creative, design, and development services for television shows, commercials, and infomercials. The Company’s strengths include research and development of cutting-edge programming for online webcasting of streaming video.
http://www.sussexavenueprofiles.com
ASNI 35% up BUY
ASNI 35% koop buy 010
From the MM board a must read
Scientific Observations on HPB84 and HCCF
--------------------------------------------------------------------------------
Greetings.
My name is Mike, and, because I am a scientist, I felt the need to throw my two cents in regarding the debate about the future of HPB84. I have to say that I am not a financial expert, nor am I very good at reading charts or leveraging probability waves. My approach to this stock was rather clinical and mundane. As soon as I saw the ingredient list, I did some scientific research into the efficacy of the compounds used in the treatment, found a wealth of scientific studies to support the antidiabetic action of each one of the seven major ingredients individually, and then I immediately bought and held.
Why did I buy and hold? Because, I immediately knew the inevitable outcome of any major clinical trial, done correctly, would be a success. How did I know this? Because I found dozens of clinical studies in the U.S. NIH (National Institute of Health) National Library of Medicine database, performed my multiple stellar medical establishments, which supports the direct antidiabetic action of each of the seven major ingredients separately. That implies that a synergystic combination of them all should prove more effective, at far lower doses than those cited in the studies.
Why would this be true? Well, those who understand the pharmacology of drug interactions also understand the "multiplicative" principle. What does this mean? The means that if Valium, for example, provides 3 "units" of sedation, and Xanax provides 5 "units" of sedation, then the total sedation you get from taking a Valium and a Xanax is not 3 + 5, or 8 units of sedative activity, but more like 3 TIMES 5, or 15 units of sedative activity. That is why it can be dangerous to mix drugs with similar pharmacokinesis, i.e., precisely due to this synergistic effect.
What does this mean for HPB84? It means that, because there are so many different phytochemicals with similar action within the product, each of which is clinically proven to be quite bioactive by itself, that the amount of each required in combination compared to the amounts cited in sole-use studies, should be remarkably lower. Although admittedly, there's no way of knowing how much lower, and each individual patient may be quite different.
Dose-response curve aside, the point is, that even though the synergistic combination may not have been tested yet, each individual ingredient in HPB84 HAS been successfully clinically tested by itself, therefore, while non-scientific personnel continue to run around like chickens with their heads cut off, worrying about the outcome of clinical trials, I was able to base my buying decision solidly on the prescient foreknowledge that the clinical trial, if conducted with a proper scientific method, CANNOT FAIL, precisely because the clinical trials of the individual indgredients have not failed. Therefore the product cannot fail. That, in conjunction with the enormous market, is a sure prescription for success.
Although there are dozens of clinical trials in the literature for each major ingredient, I have taken the liberty of compiling a list of abstracts including only one trial for each ingredient in the product, for the sake of brevity, which clinically validates its efficacy as an antidiabetic therapy. Some of the substances are even being fast-tracked into pharmaceutical production as we speak, because of their remarkable effectiveness. So, although I initially had doubts about the product being herbal in nature, I was able to remove all personal doubt after doing a proper literature search, and examining the studies below, as well as the many others which I have not listed.
Now, placing my "chemist" hat on, the only concern I had after the question of clinical effectiveness, was the integrity of the raw materials. My original understanding was that the raw materials were being imported from overseas, and it was unclear whether or not they were being assayed prior to manufacturing the product. However, recent press releases have put that issue to rest, stating that the raw materials are assayed for authenticity and potency before inclusion into the product. That statement, to those who understand pharmacology, was more important than all of the other PRs released to date.
I invite the members of this forum to read the abstracts of the clinical studies below, for themselves. I always smile when I read about people buying or selling on a knee-jerk response to some daily happenstance, whatever that may be. I smile, because I know medical science doesn't work that way. A given therapy is either scientifically valid and clinically effective, or it's not. Once in vivo effectiveness has been confirmed through double-blind trials, the hard part is over! And regardless of emotions or personal conjectures, I believe any rational fact-finder would agree, after reviewing the literature in the scientifc record, that the basis for this product is scientifically valid, and the product is clinically effective, namely because the sum of its parts has been shown to be. I invite readers to review these studies for yourselves, and draw your own conclusions.
So, if the product can't fail, then the only thing that could possibly go wrong, is corporate governance. But as a scientific professional, I think that if this company really has the slightest clue as to exactly what they have here (which I believe they do), and its multimillion-dollar potential market, that there'd be no way they would be so short sighted as to loot the company at this early stage. Similarly, I think it is trememdously myopic of investors to sell this stock short and risk being cut out of the major price gain, just to gain a few extra shares, or a measly few thousand dollars profit. This product has the potential to make us all very very rich, well into the six or seven figure range, and once investors get ahold of that and really understand the science behind the ingredients in the product, you will begin to see an immediate upswing in the stock price, as people panic to take advantage of bargain lows.
In my opinion, if the corporoate governance does fail because the company is diluting on every price gain, then the real tragedy will not be the loss of my measly few thousand dollars. I can always make that back. The real tragedy will be the loss to those who are in dire medical need of the product, who will not be able to obtain it, if the business fails. Furthermore, I also feel the company has an ethical responsibility to market this product at a price point which enables lower-middle class diabetics, who are poor, to have some way of obtaining the product. After all, when you are in the business of medicine, it's not just about dollars and cents, its about preserving human life, and human quality of life.
So, thank you for reading, and the bibliography of studies will appear in the following post.
From the MM board a must read
Scientific Observations on HPB84 and HCCF
--------------------------------------------------------------------------------
Greetings.
My name is Mike, and, because I am a scientist, I felt the need to throw my two cents in regarding the debate about the future of HPB84. I have to say that I am not a financial expert, nor am I very good at reading charts or leveraging probability waves. My approach to this stock was rather clinical and mundane. As soon as I saw the ingredient list, I did some scientific research into the efficacy of the compounds used in the treatment, found a wealth of scientific studies to support the antidiabetic action of each one of the seven major ingredients individually, and then I immediately bought and held.
Why did I buy and hold? Because, I immediately knew the inevitable outcome of any major clinical trial, done correctly, would be a success. How did I know this? Because I found dozens of clinical studies in the U.S. NIH (National Institute of Health) National Library of Medicine database, performed my multiple stellar medical establishments, which supports the direct antidiabetic action of each of the seven major ingredients separately. That implies that a synergystic combination of them all should prove more effective, at far lower doses than those cited in the studies.
Why would this be true? Well, those who understand the pharmacology of drug interactions also understand the "multiplicative" principle. What does this mean? The means that if Valium, for example, provides 3 "units" of sedation, and Xanax provides 5 "units" of sedation, then the total sedation you get from taking a Valium and a Xanax is not 3 + 5, or 8 units of sedative activity, but more like 3 TIMES 5, or 15 units of sedative activity. That is why it can be dangerous to mix drugs with similar pharmacokinesis, i.e., precisely due to this synergistic effect.
What does this mean for HPB84? It means that, because there are so many different phytochemicals with similar action within the product, each of which is clinically proven to be quite bioactive by itself, that the amount of each required in combination compared to the amounts cited in sole-use studies, should be remarkably lower. Although admittedly, there's no way of knowing how much lower, and each individual patient may be quite different.
Dose-response curve aside, the point is, that even though the synergistic combination may not have been tested yet, each individual ingredient in HPB84 HAS been successfully clinically tested by itself, therefore, while non-scientific personnel continue to run around like chickens with their heads cut off, worrying about the outcome of clinical trials, I was able to base my buying decision solidly on the prescient foreknowledge that the clinical trial, if conducted with a proper scientific method, CANNOT FAIL, precisely because the clinical trials of the individual indgredients have not failed. Therefore the product cannot fail. That, in conjunction with the enormous market, is a sure prescription for success.
Although there are dozens of clinical trials in the literature for each major ingredient, I have taken the liberty of compiling a list of abstracts including only one trial for each ingredient in the product, for the sake of brevity, which clinically validates its efficacy as an antidiabetic therapy. Some of the substances are even being fast-tracked into pharmaceutical production as we speak, because of their remarkable effectiveness. So, although I initially had doubts about the product being herbal in nature, I was able to remove all personal doubt after doing a proper literature search, and examining the studies below, as well as the many others which I have not listed.
Now, placing my "chemist" hat on, the only concern I had after the question of clinical effectiveness, was the integrity of the raw materials. My original understanding was that the raw materials were being imported from overseas, and it was unclear whether or not they were being assayed prior to manufacturing the product. However, recent press releases have put that issue to rest, stating that the raw materials are assayed for authenticity and potency before inclusion into the product. That statement, to those who understand pharmacology, was more important than all of the other PRs released to date.
I invite the members of this forum to read the abstracts of the clinical studies below, for themselves. I always smile when I read about people buying or selling on a knee-jerk response to some daily happenstance, whatever that may be. I smile, because I know medical science doesn't work that way. A given therapy is either scientifically valid and clinically effective, or it's not. Once in vivo effectiveness has been confirmed through double-blind trials, the hard part is over! And regardless of emotions or personal conjectures, I believe any rational fact-finder would agree, after reviewing the literature in the scientifc record, that the basis for this product is scientifically valid, and the product is clinically effective, namely because the sum of its parts has been shown to be. I invite readers to review these studies for yourselves, and draw your own conclusions.
So, if the product can't fail, then the only thing that could possibly go wrong, is corporate governance. But as a scientific professional, I think that if this company really has the slightest clue as to exactly what they have here (which I believe they do), and its multimillion-dollar potential market, that there'd be no way they would be so short sighted as to loot the company at this early stage. Similarly, I think it is trememdously myopic of investors to sell this stock short and risk being cut out of the major price gain, just to gain a few extra shares, or a measly few thousand dollars profit. This product has the potential to make us all very very rich, well into the six or seven figure range, and once investors get ahold of that and really understand the science behind the ingredients in the product, you will begin to see an immediate upswing in the stock price, as people panic to take advantage of bargain lows.
In my opinion, if the corporoate governance does fail because the company is diluting on every price gain, then the real tragedy will not be the loss of my measly few thousand dollars. I can always make that back. The real tragedy will be the loss to those who are in dire medical need of the product, who will not be able to obtain it, if the business fails. Furthermore, I also feel the company has an ethical responsibility to market this product at a price point which enables lower-middle class diabetics, who are poor, to have some way of obtaining the product. After all, when you are in the business of medicine, it's not just about dollars and cents, its about preserving human life, and human quality of life.
So, thank you for reading, and the bibliography of studies will appear in the following post.
News on HCCF.......Patients To Receive Personalized Audio Messages from Panel of Doctors
HUTCHINSON, Kan., June 22 /PRNewswire-FirstCall/ -- HEE Corporation (OTCPK:
HCCF), which specializes in nutraceuticals for metabolic syndrome, today
announced a revolutionary communication system between patients and physicians.
"Ask the Doctor," a free service which will be added to http://www.hee-corp.com
and http://www.hpb84.net, will allow customers to ask medical doctors specific
questions about the company's products, and a panel of physicians will respond
with personalized audio files.
"This goes way beyond your typical customer service help line," said Radley
Brooks, president of HEE Corporation. "Whether it's a question about aspirin or
a toaster, it's frustrating when customers can't get a quick, accurate answer
about a potential purchase. Submitting questions to 'Ask the Doctor,' is not
only incredibly simple, but customers get personalized, quality answers from top
medical professionals."
HEE Corporation is the only company in the nutraceutical industry to offer this
program. When the service launches next week, customers will be able to submit
questions and comments about HEE Corporation's products through the Web sites.
In response, a medical doctor will e-mail a personalized audio file directly to
the questioner. The most frequently asked questions (FAQs) will be posted on
the sites to allow visitors to review common questions and doctor's responses.
HEE Corporation recently announced the success of a 12-week pilot study for its
breakthrough product, HPB-84, a nutraceutical that safely and effectively
addresses the three major issues of Type II diabetes by reducing blood sugar
levels, eliminating insulin resistance and promoting insulin production. The
average participant showed a 26.9 percent decrease in fasting blood glucose
levels. HEE Corporation is also developing a variety of health- related
products, including HBP-WL2000, a nutraceutical designed to aid sufferers of
metabolic syndrome, a condition affecting millions that can lead to Type II
diabetes and stroke.
About HEE Corporation
Founded in Hutchinson, Kansas in December 2003, HEE Corporation (OTCPK: HCCF) is
a publicly-traded company committed to improving the quality of life through the
research, development and distribution of products, services and nutraceuticals
that address many of the causes of metabolic syndrome. Metabolic syndrome is
quickly being recognized by the medical community as one of the most prevalent
health conditions in the United States. HPB-84, manufactured in the United
States, is currently sold exclusively through http://www.hpb84.net. It contains
a proprietary blend of the following ingredients generally recognized by the FDA
as safe (GRAS). Complete company and investor information can be found at the
company Web site, http://www.hee-corp.com.
__________________
The harder you work, the luckier you get.
Albert
HPB84 Ingredients' Clinical Trials
--------------------------------------------------------------------------------
1. Bitter Gourd (Memordica Charantia)
****************************
J Ethnopharmacol. 2003 Sep;88(1):107-11. Related Articles, Links
"Antihyperglycemic effects of three extracts from Momordica Charantia."
Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK.
Department of Life Science, University of Mumbai, Kalina, Santacruz East, 400 098 Mumbai, India.
Momordica charantia (L.) (Cucurbitaceae) commonly known as bitter gourd or karela is a medicinal plant, used in Ayurveda for treating various diseases, one of which is diabetes mellitus. In this study, various extract powders of the fresh and dried whole fruits were prepared and their blood glucose lowering effect compared by administrating them orally to diabetic rats. The aqueous extract powder of fresh unripe whole fruits at a dose of 20mg/kg body weight was found to reduce fasting blood glucose by 48%, an effect comparable to that of glibenclamide, a known synthetic drug. This extract was tested for nephrotoxicity, hepatotoxicity and biochemical parameters such as SGOT, SGPT and lipid profile. The extract did not show any signs of nephrotoxicity and hepatotoxicity as judged by histological and biochemical parameters. Thus the aqueous extract powder of Momordica charantia, an edible vegetable, appears to be a safe alternative to reducing blood glucose.
PMID: 12902059 [PubMed - indexed for MEDLINE]
2. Naja Jihwa (Enicostemma Littorale)
****************************
1: Phytother Res. 2004 Mar;18(3):233-5. Related Articles, Links
"Efficacy of Enicostemma littorale in Type 2 diabetic patients."
Upadhyay UM, Goyal RK.
Smt. R. D. Gardi Government Diploma Pharmacy College, Lakhtar, Gujarat, India.
Pills prepared from Enicostemma littorale (Gentianaceae) were administered to 84 patients with Type 2 Diabetes for three months. Estimation of various biochemical parameters showed that E. littorale reduced blood glucose as well as serum insulin levels and prevented the progression of complications in diabetic patients. Significant improvement in kidney function, lipid profile and blood pressure was observed suggesting that E. littorale is an effective herbal antidiabetic. Copyright 2004 John Wiley & Sons, Ltd.
Publication Types:
Clinical Trial
Multicenter Study
PMID: 15103671 [PubMed - indexed for MEDLINE]
3. Jambul (Eugenia Jambolana)
***********************
J Ethnopharmacol. 2003 Apr;85(2-3):201-6.
"Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of Eugenia jambolana in alloxan-induced diabetic rabbits."
Sharma SB, Nasir A, Prabhu KM, Murthy PS, Dev G.
Department of Biochemistry, University College of Medical Sciences and GTB Hospital, Delhi 110095, India. Sharmasbs@rediff.com
The hypoglycaemic and hypolipidemic effect of ethanolic extract obtained from seeds of E. jambolana was investigated in alloxan-induced diabetic rabbits. Hypoglycaemic activity was assessed by reduction in fasting blood glucose (FBG) at 90min and also fall in peak blood glucose during glucose tolerance test (GTT) in sub-diabetic and mild diabetic (MD) rabbits, but in severe diabetic (SD) rabbits by reduction in FBG at 90min. Ethanolic extract (100mg/kg body weight) when given orally to sub-diabetic (AR) for 1 day, MD for 7 days and SD for 15 days showed significant fall in FBG at 90min (12% AR, 18.9% MD and 29% SD) and also produced 16.9% fall in peak blood glucose in AR and 21% in MD rabbits during GTT. When administered daily for 15 days to MD and SD rabbits, significant fall in FBG (41.3% MD, 31.6% SD) and glycosylated haemoglobin (GHb) levels (23.3% MD, 26.6% SD) were observed, while serum insulin level showed significant increase (32.8% MD, 26.9% SD). Liver and muscle glycogen content also increased. The ethanolic extract of seeds also exhibited significant hypolipidemic effect as evident from fall in total serum cholesterol (TC)/high density lipoprotein cholesterol (HDL-c) ratio, serum low density lipoprotein cholesterol (LDL-c) levels and decreased activity of HMG-CoA reductase. The histopathological studies of liver, pancreas and aorta in alcoholic extract treated diabetic groups revealed almost normal appearance.
PMID: 12639741 [PubMed - indexed for MEDLINE]
4. Fenugreek (Trigonella Foenum-Graecum)
********************************
J Med Food. 2004 Summer;7(2):153-6. Related Articles, Links
"Supplementation of fenugreek leaves lower lipid profile in streptozotocin-induced diabetic rats."
Annida B, Stanely Mainzen Prince P.
Department of Biochemistry, Annamalai University, Annamalai Nagar-608 002, Tamil Nadu, India.
The present study was undertaken to evaluate the lipid-lowering effect of fenugreek leaves in diabetes mellitus. Albino Wistar rats were randomly divided into six groups: normal untreated rats; streptozotocin (STZ)-induced diabetic rats; STZ-induced rats + fenugreek leaves (0.5 g/kg of body weight); STZ-induced rats + fenugreek leaves (1 g/kg of body weight); STZ-induced rats + glibenclamide (600 microg/kg of body weight); and STZ-induced rats + insulin (6 units/kg of body weight). Rats were made diabetic by STZ (40 mg/kg) injected intraperitoneally. Fenugreek leaves were supplemented in the diet daily to diabetic rats for 45 days, and food intake was recorded daily. Blood glucose, total cholesterol, triglycerides, and free fatty acids were determined in serum, liver, heart, and kidney. Our results show that blood glucose and serum and tissue lipids were elevated in STZ-induced diabetic rats. Supplementation of fenugreek leaves lowered the lipid profile in STZ-induced diabetic rats.
PMID: 15298761 [PubMed - indexed for MEDLINE]
5. Bengal Quince (Aegle Marmelos)
**************************
Indian J Physiol Pharmacol. 2004 Oct;48(4):476-80.
"A study of hypoglycemic and antioxidant activity of Aegle marmelos in alloxan induced diabetic rats."
Upadhya S, Shanbhag KK, Suneetha G, Balachandra Naidu M, Upadhya S.
Departments of Biochemistry, Kasturba Medical College, Manipal - 576 104.
The present study was performed to evaluate the hypoglycemic and antioxidant effect of aqueous extract of Aegle marmelos leaves (AML) on diabetic rats. Male albino rats were randomly divided into three groups: Group I: Control; Group II: Diabetic rats; and Group III: Diabetic rats administered AML. Glucose, urea and glutathione-S-transferase (GST) in plasma, glutathione (GSH) and malondialdehyde (MDA) levels in erythrocytes were estimated in all the groups at the end of four weeks. There was a decrease in blood glucose at the end of four weeks in group III animals compared with group II, however it did not reach the control levels. There was an increase in erythrocyte GSH and a decrease in MDA in group III as compared to group II. The plasma GST levels were raised in diabetic rats when compared to controls. In the group III animals, there was a decrease in GST as compared to group II. Owing to hypoglycemic and antioxidant properties, AML may be useful in the long-term management of diabetes.
PMID: 15907058 [PubMed - in process]
6. Gurmar (Gymnesta Sylvestre)
************************
J Ethnopharmacol. 1990 Oct;30(3):295-300. Related Articles, Links
"Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients."
Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER.
Department of Biochemistry, Postgraduate Institute of Basic Medical Sciences Madras, India.
The effectiveness of GS4, an extract from the leaves of Gymnema sylvestre, in controlling hyperglycaemia was investigated in 22 Type 2 diabetic patients on conventional oral anti-hyperglycaemic agents. GS4 (400 mg/day) was administered for 18-20 months as a supplement to the conventional oral drugs. During GS4 supplementation, the patients showed a significant reduction in blood glucose, glycosylated haemoglobin and glycosylated plasma proteins, and conventional drug dosage could be decreased. Five of the 22 diabetic patients were able to discontinue their conventional drug and maintain their blood glucose homeostasis with GS4 alone. These data suggest that the beta cells may be regenerated/repaired in Type 2 diabetic patients on GS4 supplementation. This is supported by the appearance of raised insulin levels in the serum of patients after GS4 supplementation.
Publication Types:
Clinical Trial
PMID: 2259217 [PubMed - indexed for MEDLINE]
7. Cinnamon (Cinnamon Zeylandicum)
***************************
Phytother Res. 2005 Mar;19(3):203-6. Related Articles, Links
"Antidiabetic effect of Cinnamomum cassia and Cinnamomum zeylanicum in vivo and in vitro."
Verspohl EJ, Bauer K, Neddermann E.
Department of Pharmacology, Institute of Medicinal Chemistry, Munster University, Hittorfstr. 58-62, 48149 Munster, Germany. verspoh@uni-muenster.de
Rats were given Cinnamomum cassia bark or extracts from Cinnamomum cassia and zeylanicum to evaluate blood glucose and plasma insulin levels in rats under various conditions. The cassia extract was superior to the zeylanicum extract. The cassia extract was slightly more efficacious than the equivalent amount of Cassia bark. A decrease in blood glucose levels was observed in a glucose tolerance test (GTT), whereas it was not obvious in rats that were not challenged by a glucose load. The elevation in plasma insulin was direct since a stimulatory in vitro effect of insulin release from INS-1 cells (an insulin secreting cell line) was observed. Thus the cassia extract has a direct antidiabetic potency. Copyright 2005 John Wiley & Sons, Ltd.
PMID: 15934022 [PubMed - in process] Albert 21-06-2005
Quite welcome, and thank you for your comments. Actually, I'd like to put together a maketing brochure for the company that truly leverages the wealth of scientific data out there for this product in an understandable way, but personally, I've already read enough to be convinced of the product's efficacy. After all, scientific study is the only thing that separates medicine from shamanism.
I only listed one study per ingredient above, but there are literally dozens of sucessful clinical trials for each ingredient that bear witness to their clinical efficacy against diabetes and/or prediabetic syndrome. That means that it is an objective scientific fact that this combination of subtances works. Period.
Here's the rub. The largest demographic for this product will be the lower or middle class. Why? Because, sadly, this demographic is more likely to get sick, because they are less likely to be able to afford comprehensive medical care and prevention.
If a rich patient is diagnosed as prediabetic, they can afford major diet and exercise changes, dieticians, personal trainers, even something as simple as a membership at the local Bally's, which can delay or prevent onset. On the other hand, chronically obese, blue-collar workers raising children on a shoestring budget cannot afford such things, and often cannot afford the time or copayment for anything except emergency medical treatment. Consequently, they are less likely to be detected as prediabetic, less likely to be able to derail prediabetic syndrome, and most likely to have initial diagnoses as full-blown diabetic.
An entry price of about $30 a bottle, or roughly $60 for a months supply, places the cost of the product well within reach of its main demand demographic, and also makes it's price comparable to what an individual within that demographic might expect to pay for a typical prescription co-payment. An effective, affordable, prescription-free adjunct or alternative to medical treatment is a sure-fire winner for those who can't or won't go to the doctor as often as they should. Just look at the widespread success of Prilosec OTC, and the cost per 30 day supply. It's doing MUCH better in bulk on the shelves of Wal Mart at low prices than Leptoprin is doing at $153 a bottle on T.V., for example. From a business standpoint, a hundred thousand bottles sold at $30 per bottle is far better than ten thousand sold at $60, and from a medical and ethical standpoint, the lower price places the product into more hands that need it.
For example, I can think of one elderly lady I personally know who needs the product, and who wants to try the product. However, she can't afford it because she's on social security. Her diabetes is not being properly controlled by the best prescription medicine can give her, and she is suffering ongoing physical deterioration as a result. Deterioration that could be prevented or reversed by HPB84. But medicare or medicaid would never pay for such a thing, so she will never get it. Is there not an ethical responsibility to make this product, which the research clearly demonstrates WILL help her, available to her?
Just some thoughts.
Albert
-----------------------------------------------------------------
HPB84 Ingredients' Clinical Trials
--------------------------------------------------------------------------------
1. Bitter Gourd (Memordica Charantia)
****************************
J Ethnopharmacol. 2003 Sep;88(1):107-11. Related Articles, Links
"Antihyperglycemic effects of three extracts from Momordica Charantia."
Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK.
Department of Life Science, University of Mumbai, Kalina, Santacruz East, 400 098 Mumbai, India.
Momordica charantia (L.) (Cucurbitaceae) commonly known as bitter gourd or karela is a medicinal plant, used in Ayurveda for treating various diseases, one of which is diabetes mellitus. In this study, various extract powders of the fresh and dried whole fruits were prepared and their blood glucose lowering effect compared by administrating them orally to diabetic rats. The aqueous extract powder of fresh unripe whole fruits at a dose of 20mg/kg body weight was found to reduce fasting blood glucose by 48%, an effect comparable to that of glibenclamide, a known synthetic drug. This extract was tested for nephrotoxicity, hepatotoxicity and biochemical parameters such as SGOT, SGPT and lipid profile. The extract did not show any signs of nephrotoxicity and hepatotoxicity as judged by histological and biochemical parameters. Thus the aqueous extract powder of Momordica charantia, an edible vegetable, appears to be a safe alternative to reducing blood glucose.
PMID: 12902059 [PubMed - indexed for MEDLINE]
2. Naja Jihwa (Enicostemma Littorale)
****************************
1: Phytother Res. 2004 Mar;18(3):233-5. Related Articles, Links
"Efficacy of Enicostemma littorale in Type 2 diabetic patients."
Upadhyay UM, Goyal RK.
Smt. R. D. Gardi Government Diploma Pharmacy College, Lakhtar, Gujarat, India.
Pills prepared from Enicostemma littorale (Gentianaceae) were administered to 84 patients with Type 2 Diabetes for three months. Estimation of various biochemical parameters showed that E. littorale reduced blood glucose as well as serum insulin levels and prevented the progression of complications in diabetic patients. Significant improvement in kidney function, lipid profile and blood pressure was observed suggesting that E. littorale is an effective herbal antidiabetic. Copyright 2004 John Wiley & Sons, Ltd.
Publication Types:
Clinical Trial
Multicenter Study
PMID: 15103671 [PubMed - indexed for MEDLINE]
3. Jambul (Eugenia Jambolana)
***********************
J Ethnopharmacol. 2003 Apr;85(2-3):201-6.
"Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of Eugenia jambolana in alloxan-induced diabetic rabbits."
Sharma SB, Nasir A, Prabhu KM, Murthy PS, Dev G.
Department of Biochemistry, University College of Medical Sciences and GTB Hospital, Delhi 110095, India. Sharmasbs@rediff.com
The hypoglycaemic and hypolipidemic effect of ethanolic extract obtained from seeds of E. jambolana was investigated in alloxan-induced diabetic rabbits. Hypoglycaemic activity was assessed by reduction in fasting blood glucose (FBG) at 90min and also fall in peak blood glucose during glucose tolerance test (GTT) in sub-diabetic and mild diabetic (MD) rabbits, but in severe diabetic (SD) rabbits by reduction in FBG at 90min. Ethanolic extract (100mg/kg body weight) when given orally to sub-diabetic (AR) for 1 day, MD for 7 days and SD for 15 days showed significant fall in FBG at 90min (12% AR, 18.9% MD and 29% SD) and also produced 16.9% fall in peak blood glucose in AR and 21% in MD rabbits during GTT. When administered daily for 15 days to MD and SD rabbits, significant fall in FBG (41.3% MD, 31.6% SD) and glycosylated haemoglobin (GHb) levels (23.3% MD, 26.6% SD) were observed, while serum insulin level showed significant increase (32.8% MD, 26.9% SD). Liver and muscle glycogen content also increased. The ethanolic extract of seeds also exhibited significant hypolipidemic effect as evident from fall in total serum cholesterol (TC)/high density lipoprotein cholesterol (HDL-c) ratio, serum low density lipoprotein cholesterol (LDL-c) levels and decreased activity of HMG-CoA reductase. The histopathological studies of liver, pancreas and aorta in alcoholic extract treated diabetic groups revealed almost normal appearance.
PMID: 12639741 [PubMed - indexed for MEDLINE]
4. Fenugreek (Trigonella Foenum-Graecum)
********************************
J Med Food. 2004 Summer;7(2):153-6. Related Articles, Links
"Supplementation of fenugreek leaves lower lipid profile in streptozotocin-induced diabetic rats."
Annida B, Stanely Mainzen Prince P.
Department of Biochemistry, Annamalai University, Annamalai Nagar-608 002, Tamil Nadu, India.
The present study was undertaken to evaluate the lipid-lowering effect of fenugreek leaves in diabetes mellitus. Albino Wistar rats were randomly divided into six groups: normal untreated rats; streptozotocin (STZ)-induced diabetic rats; STZ-induced rats + fenugreek leaves (0.5 g/kg of body weight); STZ-induced rats + fenugreek leaves (1 g/kg of body weight); STZ-induced rats + glibenclamide (600 microg/kg of body weight); and STZ-induced rats + insulin (6 units/kg of body weight). Rats were made diabetic by STZ (40 mg/kg) injected intraperitoneally. Fenugreek leaves were supplemented in the diet daily to diabetic rats for 45 days, and food intake was recorded daily. Blood glucose, total cholesterol, triglycerides, and free fatty acids were determined in serum, liver, heart, and kidney. Our results show that blood glucose and serum and tissue lipids were elevated in STZ-induced diabetic rats. Supplementation of fenugreek leaves lowered the lipid profile in STZ-induced diabetic rats.
PMID: 15298761 [PubMed - indexed for MEDLINE]
5. Bengal Quince (Aegle Marmelos)
**************************
Indian J Physiol Pharmacol. 2004 Oct;48(4):476-80.
"A study of hypoglycemic and antioxidant activity of Aegle marmelos in alloxan induced diabetic rats."
Upadhya S, Shanbhag KK, Suneetha G, Balachandra Naidu M, Upadhya S.
Departments of Biochemistry, Kasturba Medical College, Manipal - 576 104.
The present study was performed to evaluate the hypoglycemic and antioxidant effect of aqueous extract of Aegle marmelos leaves (AML) on diabetic rats. Male albino rats were randomly divided into three groups: Group I: Control; Group II: Diabetic rats; and Group III: Diabetic rats administered AML. Glucose, urea and glutathione-S-transferase (GST) in plasma, glutathione (GSH) and malondialdehyde (MDA) levels in erythrocytes were estimated in all the groups at the end of four weeks. There was a decrease in blood glucose at the end of four weeks in group III animals compared with group II, however it did not reach the control levels. There was an increase in erythrocyte GSH and a decrease in MDA in group III as compared to group II. The plasma GST levels were raised in diabetic rats when compared to controls. In the group III animals, there was a decrease in GST as compared to group II. Owing to hypoglycemic and antioxidant properties, AML may be useful in the long-term management of diabetes.
PMID: 15907058 [PubMed - in process]
6. Gurmar (Gymnesta Sylvestre)
************************
J Ethnopharmacol. 1990 Oct;30(3):295-300. Related Articles, Links
"Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients."
Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER.
Department of Biochemistry, Postgraduate Institute of Basic Medical Sciences Madras, India.
The effectiveness of GS4, an extract from the leaves of Gymnema sylvestre, in controlling hyperglycaemia was investigated in 22 Type 2 diabetic patients on conventional oral anti-hyperglycaemic agents. GS4 (400 mg/day) was administered for 18-20 months as a supplement to the conventional oral drugs. During GS4 supplementation, the patients showed a significant reduction in blood glucose, glycosylated haemoglobin and glycosylated plasma proteins, and conventional drug dosage could be decreased. Five of the 22 diabetic patients were able to discontinue their conventional drug and maintain their blood glucose homeostasis with GS4 alone. These data suggest that the beta cells may be regenerated/repaired in Type 2 diabetic patients on GS4 supplementation. This is supported by the appearance of raised insulin levels in the serum of patients after GS4 supplementation.
Publication Types:
Clinical Trial
PMID: 2259217 [PubMed - indexed for MEDLINE]
7. Cinnamon (Cinnamon Zeylandicum)
***************************
Phytother Res. 2005 Mar;19(3):203-6. Related Articles, Links
"Antidiabetic effect of Cinnamomum cassia and Cinnamomum zeylanicum in vivo and in vitro."
Verspohl EJ, Bauer K, Neddermann E.
Department of Pharmacology, Institute of Medicinal Chemistry, Munster University, Hittorfstr. 58-62, 48149 Munster, Germany. verspoh@uni-muenster.de
Rats were given Cinnamomum cassia bark or extracts from Cinnamomum cassia and zeylanicum to evaluate blood glucose and plasma insulin levels in rats under various conditions. The cassia extract was superior to the zeylanicum extract. The cassia extract was slightly more efficacious than the equivalent amount of Cassia bark. A decrease in blood glucose levels was observed in a glucose tolerance test (GTT), whereas it was not obvious in rats that were not challenged by a glucose load. The elevation in plasma insulin was direct since a stimulatory in vitro effect of insulin release from INS-1 cells (an insulin secreting cell line) was observed. Thus the cassia extract has a direct antidiabetic potency. Copyright 2005 John Wiley & Sons, Ltd.
PMID: 15934022 [PubMed - in process] Albert 21-06-2005
HPB84 Ingredients' Clinical Trials
--------------------------------------------------------------------------------
1. Bitter Gourd (Memordica Charantia)
****************************
J Ethnopharmacol. 2003 Sep;88(1):107-11. Related Articles, Links
"Antihyperglycemic effects of three extracts from Momordica Charantia."
Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK.
Department of Life Science, University of Mumbai, Kalina, Santacruz East, 400 098 Mumbai, India.
Momordica charantia (L.) (Cucurbitaceae) commonly known as bitter gourd or karela is a medicinal plant, used in Ayurveda for treating various diseases, one of which is diabetes mellitus. In this study, various extract powders of the fresh and dried whole fruits were prepared and their blood glucose lowering effect compared by administrating them orally to diabetic rats. The aqueous extract powder of fresh unripe whole fruits at a dose of 20mg/kg body weight was found to reduce fasting blood glucose by 48%, an effect comparable to that of glibenclamide, a known synthetic drug. This extract was tested for nephrotoxicity, hepatotoxicity and biochemical parameters such as SGOT, SGPT and lipid profile. The extract did not show any signs of nephrotoxicity and hepatotoxicity as judged by histological and biochemical parameters. Thus the aqueous extract powder of Momordica charantia, an edible vegetable, appears to be a safe alternative to reducing blood glucose.
PMID: 12902059 [PubMed - indexed for MEDLINE]
2. Naja Jihwa (Enicostemma Littorale)
****************************
1: Phytother Res. 2004 Mar;18(3):233-5. Related Articles, Links
"Efficacy of Enicostemma littorale in Type 2 diabetic patients."
Upadhyay UM, Goyal RK.
Smt. R. D. Gardi Government Diploma Pharmacy College, Lakhtar, Gujarat, India.
Pills prepared from Enicostemma littorale (Gentianaceae) were administered to 84 patients with Type 2 Diabetes for three months. Estimation of various biochemical parameters showed that E. littorale reduced blood glucose as well as serum insulin levels and prevented the progression of complications in diabetic patients. Significant improvement in kidney function, lipid profile and blood pressure was observed suggesting that E. littorale is an effective herbal antidiabetic. Copyright 2004 John Wiley & Sons, Ltd.
Publication Types:
Clinical Trial
Multicenter Study
PMID: 15103671 [PubMed - indexed for MEDLINE]
3. Jambul (Eugenia Jambolana)
***********************
J Ethnopharmacol. 2003 Apr;85(2-3):201-6.
"Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of Eugenia jambolana in alloxan-induced diabetic rabbits."
Sharma SB, Nasir A, Prabhu KM, Murthy PS, Dev G.
Department of Biochemistry, University College of Medical Sciences and GTB Hospital, Delhi 110095, India. Sharmasbs@rediff.com
The hypoglycaemic and hypolipidemic effect of ethanolic extract obtained from seeds of E. jambolana was investigated in alloxan-induced diabetic rabbits. Hypoglycaemic activity was assessed by reduction in fasting blood glucose (FBG) at 90min and also fall in peak blood glucose during glucose tolerance test (GTT) in sub-diabetic and mild diabetic (MD) rabbits, but in severe diabetic (SD) rabbits by reduction in FBG at 90min. Ethanolic extract (100mg/kg body weight) when given orally to sub-diabetic (AR) for 1 day, MD for 7 days and SD for 15 days showed significant fall in FBG at 90min (12% AR, 18.9% MD and 29% SD) and also produced 16.9% fall in peak blood glucose in AR and 21% in MD rabbits during GTT. When administered daily for 15 days to MD and SD rabbits, significant fall in FBG (41.3% MD, 31.6% SD) and glycosylated haemoglobin (GHb) levels (23.3% MD, 26.6% SD) were observed, while serum insulin level showed significant increase (32.8% MD, 26.9% SD). Liver and muscle glycogen content also increased. The ethanolic extract of seeds also exhibited significant hypolipidemic effect as evident from fall in total serum cholesterol (TC)/high density lipoprotein cholesterol (HDL-c) ratio, serum low density lipoprotein cholesterol (LDL-c) levels and decreased activity of HMG-CoA reductase. The histopathological studies of liver, pancreas and aorta in alcoholic extract treated diabetic groups revealed almost normal appearance.
PMID: 12639741 [PubMed - indexed for MEDLINE]
4. Fenugreek (Trigonella Foenum-Graecum)
********************************
J Med Food. 2004 Summer;7(2):153-6. Related Articles, Links
"Supplementation of fenugreek leaves lower lipid profile in streptozotocin-induced diabetic rats."
Annida B, Stanely Mainzen Prince P.
Department of Biochemistry, Annamalai University, Annamalai Nagar-608 002, Tamil Nadu, India.
The present study was undertaken to evaluate the lipid-lowering effect of fenugreek leaves in diabetes mellitus. Albino Wistar rats were randomly divided into six groups: normal untreated rats; streptozotocin (STZ)-induced diabetic rats; STZ-induced rats + fenugreek leaves (0.5 g/kg of body weight); STZ-induced rats + fenugreek leaves (1 g/kg of body weight); STZ-induced rats + glibenclamide (600 microg/kg of body weight); and STZ-induced rats + insulin (6 units/kg of body weight). Rats were made diabetic by STZ (40 mg/kg) injected intraperitoneally. Fenugreek leaves were supplemented in the diet daily to diabetic rats for 45 days, and food intake was recorded daily. Blood glucose, total cholesterol, triglycerides, and free fatty acids were determined in serum, liver, heart, and kidney. Our results show that blood glucose and serum and tissue lipids were elevated in STZ-induced diabetic rats. Supplementation of fenugreek leaves lowered the lipid profile in STZ-induced diabetic rats.
PMID: 15298761 [PubMed - indexed for MEDLINE]
5. Bengal Quince (Aegle Marmelos)
**************************
Indian J Physiol Pharmacol. 2004 Oct;48(4):476-80.
"A study of hypoglycemic and antioxidant activity of Aegle marmelos in alloxan induced diabetic rats."
Upadhya S, Shanbhag KK, Suneetha G, Balachandra Naidu M, Upadhya S.
Departments of Biochemistry, Kasturba Medical College, Manipal - 576 104.
The present study was performed to evaluate the hypoglycemic and antioxidant effect of aqueous extract of Aegle marmelos leaves (AML) on diabetic rats. Male albino rats were randomly divided into three groups: Group I: Control; Group II: Diabetic rats; and Group III: Diabetic rats administered AML. Glucose, urea and glutathione-S-transferase (GST) in plasma, glutathione (GSH) and malondialdehyde (MDA) levels in erythrocytes were estimated in all the groups at the end of four weeks. There was a decrease in blood glucose at the end of four weeks in group III animals compared with group II, however it did not reach the control levels. There was an increase in erythrocyte GSH and a decrease in MDA in group III as compared to group II. The plasma GST levels were raised in diabetic rats when compared to controls. In the group III animals, there was a decrease in GST as compared to group II. Owing to hypoglycemic and antioxidant properties, AML may be useful in the long-term management of diabetes.
PMID: 15907058 [PubMed - in process]
6. Gurmar (Gymnesta Sylvestre)
************************
J Ethnopharmacol. 1990 Oct;30(3):295-300. Related Articles, Links
"Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients."
Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER.
Department of Biochemistry, Postgraduate Institute of Basic Medical Sciences Madras, India.
The effectiveness of GS4, an extract from the leaves of Gymnema sylvestre, in controlling hyperglycaemia was investigated in 22 Type 2 diabetic patients on conventional oral anti-hyperglycaemic agents. GS4 (400 mg/day) was administered for 18-20 months as a supplement to the conventional oral drugs. During GS4 supplementation, the patients showed a significant reduction in blood glucose, glycosylated haemoglobin and glycosylated plasma proteins, and conventional drug dosage could be decreased. Five of the 22 diabetic patients were able to discontinue their conventional drug and maintain their blood glucose homeostasis with GS4 alone. These data suggest that the beta cells may be regenerated/repaired in Type 2 diabetic patients on GS4 supplementation. This is supported by the appearance of raised insulin levels in the serum of patients after GS4 supplementation.
Publication Types:
Clinical Trial
PMID: 2259217 [PubMed - indexed for MEDLINE]
7. Cinnamon (Cinnamon Zeylandicum)
***************************
Phytother Res. 2005 Mar;19(3):203-6. Related Articles, Links
"Antidiabetic effect of Cinnamomum cassia and Cinnamomum zeylanicum in vivo and in vitro."
Verspohl EJ, Bauer K, Neddermann E.
Department of Pharmacology, Institute of Medicinal Chemistry, Munster University, Hittorfstr. 58-62, 48149 Munster, Germany. verspoh@uni-muenster.de
Rats were given Cinnamomum cassia bark or extracts from Cinnamomum cassia and zeylanicum to evaluate blood glucose and plasma insulin levels in rats under various conditions. The cassia extract was superior to the zeylanicum extract. The cassia extract was slightly more efficacious than the equivalent amount of Cassia bark. A decrease in blood glucose levels was observed in a glucose tolerance test (GTT), whereas it was not obvious in rats that were not challenged by a glucose load. The elevation in plasma insulin was direct since a stimulatory in vitro effect of insulin release from INS-1 cells (an insulin secreting cell line) was observed. Thus the cassia extract has a direct antidiabetic potency. Copyright 2005 John Wiley & Sons, Ltd.
PMID: 15934022 [PubMed - in process] Albert 21-06-2005